Original Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 14, 2013; 19(34): 5622-5632
Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5622
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flow chart of the patients included in the study. TACE: Transcatheter arterial chemoembolization; DEB: Doxorubicin-eluting bead; HCC: Hepatocellular carcinoma; LT: Liver transplantation; PEA: Percutaneous ethanol ablation; RFA: Radiofrequency tumor ablation; c-TACE: Conventional TACE.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Inflammatory and fibrotic changes in the tissue surrounding the tumor nodules. TACE: Transcatheter arterial chemoembolization; DEB: Doxorubicin-eluting bead.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Recurrence-free survival probabilities according to the following. A: Pre-transplant treatment type (log-rank P = 0.0493); B: Adherence to Milan Criteria at pathology (log-rank P < 0.0001); C: Percentage of necrosis in the cumulative tumor area (log-rank P = 0.0098); D: Pre-transplant serum α-fetoprotein level (log-rank P = 0.0008). TACE: Transcatheter arterial chemoembolization; DEB: Doxorubicin-eluting bead; LT: Liver transplantation; CTA: Cumulative tumor area; c-TACE: Conventional TACE.